Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Torrent Pharma

Growth unavailable

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, as printed in the company's Q2 FY27 results press release dated 23 Oct 2026

Reported revenue (₹ crore, as printed (rounded to whole crore)): 4,979

Read summary and comparison caveats

Torrent Pharma's Q2 FY27 consolidated revenue was ₹4,979 crore against ₹3,302 crore a year earlier (printed +50.8%), while PAT was ₹534 crore against ₹591 crore (printed -9.6%). Operating EBITDA before exceptional items was ₹1,666 crore at a printed margin of 33.5%.

  • Figures are from the company's own Q2 FY27 results press release (4-page PDF, Ahmedabad, 23 Oct 2026, hosted on torrentpharma.com), read in full on 15 Nov 2026. It is a press release summary, not the filed results statement, so only the lines it prints are shown, rounded as printed. It prints year-on-year comparisons and no quarter-on-quarter columns, so none are shown or derived.
  • Comparability, from the release: it refers to the merger, effective 8 July 2026, with its JB business. JB business revenue is printed as ₹1,086 crore of the ₹4,979 crore total, and base business revenue as ₹3,893 crore (printed +18%). The release prints the JB split only for Q2 FY27, so the printed total growth of 51% is not a like-for-like base comparison; the +18% is the release's base business figure.
  • Base business as printed: India ₹2,181 crore (+20%), Brazil ₹440 crore (+38%), United States ₹417 crore (+24%), Germany ₹283 crore (-7%). The release says integration of JB led to a transient impact on revenues in Q2 FY27 and attributes Germany's decline to a third-party supplier disruption and loss of certain high volume tenders.
  • H1 FY27 as printed: revenues ₹9,900 crore (₹6,480 crore in H1 FY26), operating EBITDA ₹3,330 crore, PAT ₹1,100 crore (₹1,139 crore), exceptional item ₹(31) crore.
  • Company statements, attributed: market-share and growth comparisons in the release (for example India growth against IPM growth of 12%, Gx Semaglutide share of 32%) are the company's own, citing PharmaTrac and IQVIA, and are not verified here.

Checked 15 Nov 2026

Open original filing
Read the complete published results desk